Abstract: A solid detergent composition comprising a cationic polymer (A) and an anionic surfactant (B), wherein the cationic polymer (A) and the anionic surfactant (B) satisfy the following requirement I and requirement II: Requirement I: a transmittance of a mixed liquid 1 obtained by mixing the cationic polymer (A), the anionic surfactant (B), and water at a weight ratio of 0.5:12:87.5 to light having a wavelength of 655 nm (optical path length: 1 cm, 25° C.) is 95% or more, and Requirement II: a transmittance of a diluted liquid obtained by mixing the mixed liquid 1 and water at a weight ratio of 1:4 to light having a wavelength of 655 nm (optical path length: 1 cm, 25° C.) is 90% or less.

Abstract: A slurry dispersion containing (A) one or more selected from trimethylsiloxysilicic acid and derivatives thereof, (B) a hydrophobized coloring pigment, and (C) an oil that is liquid at 25° C., wherein blending with a cosmetic provides a good feel on use (light feel), good applicability (spread), and an excellent feeling of adhesion and suppresses color unevenness by improving pigment dispersibility.

Abstract: The present invention is related to novel lip gloss-type cosmetic composition comprising (a) hydrocarbon-based wax purified from natural gas or petroleum with a melting point of 85° C. or higher, (b) oligomer-type phytosterol ester, (c) fatty acid complex ester oil, (d) polymeric film forming agent, and (e) a gelling agent including an organic modified clay mineral, which is in a solid stick form having high gloss and a sense of use such as liquid or semi-solid lip gloss.

Abstract: An objective of the present invention is to provide an oil-in-water emulsion cosmetic in which a UV absorbing agent and a pigment can be stably blended, having excellent vibration stability while also having improved makeup effects such as compatibility with skin, uniformity of the coating film, and non-thickly-coated appearance. The oil-in-water emulsion cosmetic of the present invention contains (A) a vesicle-forming amphiphilic substance, (B) an oil component containing a UV absorbing agent other than ethylhexyl methoxycinnamate, and (C) an amino acid surface-treated pigment.

Abstract: The present invention relates to the field of perfumery. More particularly, it concerns a consumer product comprising at least one compound of formula (I) and, optionally, a personal care active base. Moreover, the present invention relates to a method of imparting a long-lasting odor, in particular green odor, to surfaces, such as skin or hair.

Abstract: A continuous administration device configured to be indwelled in a living body for sustained release of a substance to be administered, the continuous administration device including: a cylindrical main body portion having an inner cavity; a plug slidable in the inner cavity in a liquid-tight manner; a pressing portion disposed on an upstream side with respect to the plug and configured to press the plug toward a downstream side; the substance to be administered, which is stored in the inner cavity on the downstream side with respect to the plug and released into the living body by the plug sliding toward the downstream side; and a sliding solid coating layer that reduces initial sliding resistance and normal sliding resistance of the plug, on at least one of an outer surface of the plug or a region where the plug slides in the inner cavity.

Abstract: A injectable pharmaceutical compositions consists of a buffered aqueous solution comprising (a) about 5% w/v to about 15% w/v sulfobutylether-?-cyclodextrin (SBE-?-CD), and about 0.05% w/v to about 0.5% w/v ibudilast, or (b) about 5% w/v to about 25% w/v polyoxyl castor oil, and about 1% w/v to about 5% w/v ibudilast.

Abstract: The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Abstract: Provided herein are drug implants comprising apalutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and apalutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.

Abstract: An oral product comprising an antiviral active ingredient for use in a method of treatment or prevention of an infection with a coronavirus, an influenza virus, a coxsackievirus, or a herpes virus is disclosed. An oral product comprising spermidine and one or more polyphenols, such as quercetin and isoquercetin as an antiviral active ingredient is also disclosed. The oral product may further include propolis, manuka-honey, natural extracts and/or essential oils as antiviral active ingredients. In addition, a method for producing said oral products is disclosed.

Abstract: Pharmaceutical compositions of epinephrine and its prodrugs are described and the compositions having enhanced active component permeation properties are described as being administered with specific residence times.

Abstract: The technology described herein is directed to ionic liquids and methods of drug delivery.

Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

Abstract: The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.

Abstract: The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to the use of a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).

Abstract: A comprehensive addiction treatment method with a medication delivery system of subcutaneous implant of micro-pellets in patients, which may include a method of identification at an advanced video communication system through facial recognition, voice recognition and/or a recognition of an RFID microchip implanted in a patient. The identification will be transmitted over the Internet to a database at a secure server to initiate a computer program to stream video content, computer generated communication and/or a live video to be transmitted to an audio-visual system that may be capable of displaying a life-size video image of a live caregiver or a computer generated avatar of a caregiver within a three dimensional setting for real time two-way communication with apparent eye contact.

Abstract: The disclosure provides a carotenoid preparation, its preparation method and application. The method includes: obtaining pretreated carotenoid by mixing carotenoid and ethanol aqueous solution, stirring, and then dispersing through high-speed shearing, adding antioxidant, and removing solvent until ethanol solution residue is less than 10 ppm, a moisture content of the pretreated carotenoid being within a range of 10%-30%; obtaining a pretreated gelling wall material by preparing an aqueous solution with a first solid content through mixing wall material and carbohydrate, stirring, and dispersing; and obtaining the carotenoid preparation by mixing the pretreated carotenoid and the pretreated gelling wall material, emulsifying, and granulating.

Abstract: A system for producing a microsphere includes a first raw material storing to store a first raw material is stored, a second raw material storing part to store a second raw material including a solvent, a biodegradable polymer, and a drug, an emulsion generating part to continuously form an emulsion including the first raw material of a continuous phase and the second raw material of a dispersed phase, a first solvent extracting and removing part to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere, and a second solvent extracting and removing part spaced apart from the first solvent extracting and removing part, to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere.

Abstract: A method for producing entacapone tablets, including auxiliary materials passing screening, batching, mixing, sieving, mixing, drying granulation, sieving, mixing with magnesium stearate and pressing finished products. Mannitol, a supplementary material, was prepared by following steps: the mixture of fructose and glucose was hydrolyzed from sucrose; The glucose obtained was further hydrolyzed to obtain a mixture of mannose, fructose and glucose; The mannitol product is obtained by mixing the mannose, fructose and glucose obtained in steps 1 and 2, hydrogenation, refining, concentration, crystallization and pressure filtration; The finished mannitol product is dried and crushed by mixing with water mixed with binder. The compressed mannitol particles with a particle size of 200-350 um are obtained, which are used as auxiliary materials for the preparation of entacapone tablets.

Abstract: The present disclosure relates to a preparation method for a preparation, in particular, to a compound sustained-release composition of naltrexone and risperidone, and a preparation method therefor and an application thereof. The compound sustained-release composition of naltrexone and risperidone and its preparation provided in the present disclosure may be sustainably released in vitro for more than 12 weeks, the release conforms to zeroth-order approximation mode, and the release rate is stable; the suitable preparation method and parameter control are adopted in the present disclosure, so that naltrexone sustained-release microspheres and risperidone sustained-release microspheres are released synchronously, and an administration period is easier to control; further, the product provided by the present disclosure has a good effect in methamphetamine addiction tests, and can be used for preparing products for the treatment of methamphetamine addiction.

Abstract: In masking particles comprising a drug-containing particle containing a drug of a salt with an acid and containing a carbonate, the drug-containing particle being coated with a coating layer containing a water-insoluble polymer, drug release in the oral cavity and pharynx is sufficiently suppressed, the drug is rapidly released after swallowing, and the release suppression time of the drug is easily controlled. The drug-containing particle may comprise a core particle and an interlayer on the core particle, and the core particle may contain the drug of a salt with an acid, and the interlayer contains the carbonate, or the core particle may contain the carbonate, and the interlayer may contain the drug of a salt with an acid.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: The invention discloses a solid dispersion, a pharmaceutical preparation, a preparation method and an application thereof. The solid dispersion of the invention comprises carriers and active constituents, which is a compound as shown in formula (I) and/or a pharmaceutically acceptable salt thereof; The carrier is “homopolymer and copolymer of N-vinyl lactam” and/or pH-dependent cellulose derivatives. The preparation of the invention comprises the solid dispersion, fillers and disintegrating agents. The solid dispersion of the invention has good dissolution and significantly improves the solubility of effective constituents. The preparation can effectively improve the bioavailability of Bcl-2 inhibitor, has good dissolution and stability, and can improve the safety of a medication.

Abstract: This invention relates to the direct delivery of a vitamin composition to the large intestine, in order to decrease the growth of pathogenic organisms in the gut, such as Adherent Invasive E. coli (AIEC), Salmonella enteriditis and Clostridium difficile. The vitamin composition comprises a combination of the following vitamins: Vitamin C, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6 and folic acid.

Abstract: Provided is a novel soft capsule. The soft capsule has a shell comprising gellan gum, wherein the soft capsule satisfies the following requirements: (A) the soft capsule has a disintegration time of 60 minutes or less as measured by a disintegration test method specified in the Japanese Pharmacopoeia using water as a test medium; and/or (B) the soft capsule has a ratio of a crush strength (g) to an outer diameter. (mm) (crush strength/outer diameter ratio) of 210 or more.

Abstract: The present invention relates to a composition for encapsulation in a soft gelatin shell which comprises ibuprofen, one or more polyoxysorbitan esters and a base wherein the weight ratio of the one or more polyoxysorbitan esters to ibuprofen is from 0.1:1-0.9:1, the weight ratio of the base to ibuprofen is from 1:6-1:20 and the weight ratio of the one or more polyoxysorbitan esters to base is 1:1-13:1 and wherein the ibuprofen is present at an amount of 50%-65% w/w.

Abstract: Method for manufacturing microcapsules comprising a wall made of polymer material containing an active substance, comprising the following steps: —preparing an oil phase comprising a poly(beta-aminoester) prepolymer, and an active substance constituting the phase to be encapsulated; preparing an aqueous phase comprising at least one surfactant; preparing an O/W (oil in water) emulsion by adding the oil phase to the aqueous phase; and initiating radical polymerisation with in the emulsion. A polymerisation initiator must be present in the aqueous and/or oil phase.

Abstract: A process is provided for encapsulating glutathione (GSH), 3,3?-diindolylmethane (DIM), coenzyme-Q10 (CoQ10), and other hydrophobic antioxidant compounds by using whey proteins which may be polymerized in a particular manner. Further, compositions comprising polymerized whey protein (PWP) encapsulated glutathione, polymerized whey protein (PWP) encapsulated CoQ10, and polymerized whey protein (PWP) encapsulated DIM are provided.

Abstract: The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.

Abstract: This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate.

Abstract: The present invention relates to a method for rapidly obtaining albumin nanoparticles loaded with magnetic nanoparticles, which comprises steps with ultra-high speed agitation. This method allows obtaining said nanoparticles in less than minutes with encapsulation efficiency higher than 90%.

Abstract: A method of treating cough includes applying a therapeutic foot patch to a bottom of a foot. The therapeutic foot patch has a flexible backing with a skin contact side that contacts the bottom of the foot. An active ingredient carrier section on the skin contact side carries a cough-reducing active ingredient that imparts a chemesthetic sensation to the foot.

Abstract: The present invention relates to aransdermal therapeutic system for the transdermal administration of a systemically active agent having a self-adhesive layer structure. The transdermal therapeutic system includes (A) a backing layer, and (B) a dried biphasic layer. The dried biphasic layer has (a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and (b) an inner phase having a composition that includes at least one active agent. The inner phase forms dispersed deposits in the outer phase, with the dried biphasic layer including (c) from 0.1% to 3.5% of an interface mediator other than silicone oil, with the interface mediator having with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C.

Abstract: A ropinirole-containing patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer comprising: at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof; at least one sodium carboxylate selected from the group consisting of sodium pentanoate, disodium glutarate, and sodium hexanoate; and an adhesive agent.

Abstract: A transdermal delivery system is described, where the system comprises a drug reservoir layer comprising an active agent and a skin contact adhesive layer. A microporous membrane that has been pretreated with a membrane treatment composition before the membrane is incorporated into the system is disposed between the drug reservoir layer and the skin contact adhesive layer.

Abstract: The present disclosure provides a multivitamin specifically formulated with an amended non-staining beta-carotene, or pro-vitamin A. In another aspect, the present disclosure provides a multivitamin for patients undergoing CFTR modulator therapy. The multivitamin includes, in various embodiments, pro-vitamin A, vitamin E, a solubilizer, a bile fluid secretion stimulator, vitamin C and a probiotic formulation.

Abstract: The present disclosure relates to a nutritional composition for inhibiting survival of an RNA virus and a method for treating an RNA virus infection. The nutritional composition consists of an astaxanthin extract and at least one probiotic extract. The at least one probiotic extract is selected from the group consisting of a lipoteichoic acid and a peptidoglycan. The method for treating the RNA virus infection includes administering an effective concentration of a nutritional composition to a subject in need thereof, wherein the nutritional composition consists of an astaxanthin extract and at least one probiotic extract, and the at least one probiotic extract is selected from the group consisting of a lipoteichoic acid and a peptidoglycan.

Abstract: Herein is described a pharmaceutical composition for agonizing CB2 receptor activity, medical kits, therapeutic applications thereof, and methods of making and using such compositions. The composition comprises a combination of: —a first compound of Formula I: (E1) or a pharmaceutically acceptable salt thereof; and —a second compound of Formula II: (E2) or a pharmaceutically acceptable salt thereof.

Abstract: Provided in the present invention are a coenzyme Q10 microemulsion, a preparation method therefor and the use thereof. The coenzyme Q10 microemulsion is prepared from components comprising coenzyme Q10, a carrier oil, an anti-crystallization agent, a lipophilic emulsifier, a hydrophilic emulsifier, a co-emulsifier and water. The microemulsion has a particle size DV(90) of between 20 nm and 80 nm, and is clear, transparent, free of demulsification and high in bioavailability, can be stably stored for a long time at normal temperatures and in extreme temperature environments. In addition, the microemulsion is suitable for the pharmaceutical, cosmetic and food fields, especially for beverages, oral liquids and other products. Also provided in the present invention is a method for preparing the coenzyme Q10 microemulsion, which is simple in equipment, low in cost and easy in operation.

Abstract: Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexylamine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject.

Abstract: The present invention discloses the use of an alkaloid compound in the preparation of products for the prevention and/or treatment of cardiac damage. Activity studies are conducted on the alkaloid compound, and it is verified that the alkaloid compound provided by the present invention is capable of inhibiting apoptosis induced by cardiotoxic effects. Specifically, it can inhibit cardiomyocyte apoptosis induced by the anthracycline DOX by down-regulating the expression level of p-JNK and/or Cleaved-Caspase-3, thus preventing and/or treating cardiomyocyte toxicity. The alkaloid compound can be used in the preparation of drugs for the prevention and/or treatment of diseases related to cardiac damage.

Abstract: A pharmaceutical composition useful for the local administration onto the tympanic membrane and diffusion through the tympanic membrane without perforation of the membrane, for use in the treatment of an ear disorder or a neurological disorder such as hearing loss. Also, a device useful for the local administration onto the tympanic membrane of the pharmaceutical formulation of the invention.

Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.

Abstract: Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

Abstract: A method for preparing compound or biological drug enhancing CNPase activity for treating heart diseases. The chemical method relates to using kaurane compounds to up-regulating the expression and activity of CNPase. Biological therapeutic drugs related to the preparation of CNPase enzyme expressed by using recombinant adeno-associated virus and local interventional therapy. In a rat myocardial hypertrophy and heart failure model, the methods can effectively improve myocardial hypertrophy, myocardial remodeling, inhibit myocardial hypertrophy and fibrosis, and increase cardiac function.

Abstract: The present application relates to GHB formulations and methods for manufacturing the same.

Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.

Abstract: The present disclosure provides compositions and methods for their use in the treatment and/or prevention of a ferrotoxic disease, an iron related disease or disorder, or a cancer, the compositions comprising a D-cysteine or a D-derivative thereof, an isomer or a salt of said D-cysteine or derivative.